Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

The event hosted by the Worth Avenue Association begins at 1 p.m. May 3 and wraps up with a fashion show and hat contest in Via Mizner at 5 p.m.

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 ...

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Fintel reports that on April 28, 2025, Cantor Fitzgerald initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a ...

Analysts Rahman and McCarthy hold a conference call with CFO Zante on April 30 hosted by Maxim Group.Stay Ahead of the Market: Discover ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at ...